Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Program to Study the Preventive Efficacy of the BiVac Polio (Oral Polio Vaccine, Divalent, Live Attenuated of Types 1 and 3 ) Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19, Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers Aged 18-65

NCT05083039 is registered in ClinicalTrials.gov with Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products as lead sponsor.

NCT NCT05083039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05083039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Program to Study the Preventive Efficacy of the BiVac Polio (Oral Polio Vaccine, Divalent, Live Attenuated of Types 1 and 3 ) Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19, Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products", on Volunteers Aged 18-65
Lead sponsor
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Phase
Observational
Overall status
Completed
Start date
May 14, 2020
Completion date
September 3, 2021
Enrollment
1,500 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infections, polio, vaccine